ReachMD สาธารณะ
[search 0]
เพิ่มเติม
ดาวน์โหลดแอปเลย!
show episodes
 
Artwork

1
ReachMD CME

ReachMD

Unsubscribe
Unsubscribe
รายสัปดาห์+
 
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.
  continue reading
 
Loading …
show series
 
CME credits: 0.25 Valid until: 31-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/empowering-choices-navigating-early-stage-hr-her2-breast-cancer-with-cdk46-inhibition/26643/ Hormone receptor-positive, HER2-negative cancer is the most common subtype of breast cancer. Initial treatment consists of surgery with or without radiothera…
  continue reading
 
CME credits: 1.00 Valid until: 17-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/pulmonary-hypertension-for-advanced-practice-providers-risk-stratification-and-diagnosis-to-enhance-quality-of-care-and-outcomes/27146/ This program focuses on early symptom identification and timely diagnosis in patients with pulmonary hypertension …
  continue reading
 
CME credits: 0.25 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/patient-centric-approaches-to-optimizing-outcomes-in-aad-case-review/26713/ Early diagnosis and management of agitation in Alzheimer’s disease (AAD) is part of a comprehensive treatment plan. How can you help caregivers recognize subtle signs of AAD …
  continue reading
 
CME credits: 1.00 Valid until: 11-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/bridging-distances-in-pah-bringing-best-practices-to-the-people-through-telemonitoring/24051/ Pulmonary Arterial Hypertension (PAH) requires a personalized, multidisciplinary approach, which is often lacking in remote regions due to limited access to…
  continue reading
 
CME credits: 1.00 Valid until: 11-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/advancing-cystic-fibrosis-addressing-disparities-challenging-perceptions-and-innovating-patient-centered-care/24487/ Cystic Fibrosis (CF) care faces challenges from health disparities, limited access, and unintended bias, affecting patient outcomes. …
  continue reading
 
CME credits: 0.25 Valid until: 04-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/navigating-copd-from-symptom-recognition-to-emerging-treatment-strategies/26928/ Listen in as Farrukh Abbas, MD, FCCP, and Megan Conroy, MD, MAEd, FCCP, discuss the role of the care team in COPD diagnosis, recent changes in classifications and update…
  continue reading
 
CME credits: 1.00 Valid until: 04-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/bringing-treatment-into-focus-biomarker-driven-first-line-therapy-for-metastatic-gastricgej-cancers/26719/ This educational activity delves into biomarker-driven strategies for first-line therapy in metastatic gastric and gastroesophageal junction (G…
  continue reading
 
CME credits: 0.75 Valid until: 02-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-evolving-role-of-met-tkis-in-nsclc/17986/ The MET pathway can be activated by MET exon 14 skipping mutations, gene amplification, or overexpression. Mutations within this pathway carry a poor prognosis for patients with non-small cell lung cancer…
  continue reading
 
CME credits: 0.25 Valid until: 30-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/chairpersons-perspective-redefining-treatment-across-the-spectrum-of-hrher2-expressing-metastatic-breast-cancer/26625/ This Chairperson’s Perspective will provide an in-depth look at ADC-directed therapies for HR+/HER2-expressing metastatic breast ca…
  continue reading
 
CME credits: 1.00 Valid until: 25-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/mastering-the-complexity-of-aml-treatment-a-multidimensional-approach-to-diagnosis-therapy-and-side-effect-management/26723/ While the expanding arsenal of therapies available for patients with AML allows practitioners to further hone treatment and i…
  continue reading
 
CME credits: 0.25 Valid until: 25-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/implementing-a-multidisciplinary-approach-to-heart-failure-patient-identification-and-treatment-using-novel-device-therapy/16191/ Despite guideline-directed medical therapy, many patients with heart failure will continue to develop worsening symptoms…
  continue reading
 
CME credits: 1.00 Valid until: 24-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/noncovalent-btk-inhibitors-new-targeted-options-for-relapsed-or-refractory-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma/24362/ This program addresses the educational needs for relapsed or refractory (R/R) B-cell leukemias and lymphomas, part…
  continue reading
 
CME credits: 0.25 Valid until: 18-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/how-antibody-based-therapies-are-revolutionizing-its-management/26371/ Warm autoimmune hemolytic anemia (wAIHA) is a rare condition characterized by the premature destruction of red blood cells mainly by pathogenic IgG optimally active at 37oC. Innov…
  continue reading
 
CME credits: 0.50 Valid until: 13-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/targeting-resistance-in-egfrm-nsclc-with-her3-directed-adcs-in-the-community-setting/24489/ The treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC) that has progressed on EGFR TKI therapy remains a clinical challenge, as traditional…
  continue reading
 
CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/patient-case-how-do-her2-directed-therapies-fit-into-the-biliary-tract-cancer-treatment-landscape/26795/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implicat…
  continue reading
 
CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/emerging-data-evaluating-her2-directed-therapies-in-gynecologic-cancers/26792/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapie…
  continue reading
 
CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/patient-case-how-do-her2-directed-therapies-fit-into-the-ovarian-cancer-treatment-landscape/26794/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications f…
  continue reading
 
CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/pivotal-data-on-targeting-her2-in-her2-expressing-solid-tumors/26791/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and cli…
  continue reading
 
CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/monitoring-and-managing-treatment-related-adverse-effects-associated-with-her2-directed-agents/26793/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implication…
  continue reading
 
CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/diversity-in-her2-expression-among-gynecologic-cancers/26790/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical de…
  continue reading
 
CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/her2-testing-strategies-across-tumor-types-amidst-guidelines-gaps/26789/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and …
  continue reading
 
CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/significance-of-her2-expression-in-solid-tumors/26788/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-…
  continue reading
 
CME credits: 1.25 Valid until: 16-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-challenge-of-bcl-2-resistance-in-cll-treatment-strategies-and-emerging-therapies/26503/ Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients a…
  continue reading
 
CME credits: 1.25 Valid until: 16-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/frontline-fixed-duration-therapy-in-cll-improving-outcomes-and-tolerability/26495/ Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older …
  continue reading
 
CME credits: 1.25 Valid until: 16-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/overcoming-disease-progression-in-cll-evidence-based-re-treatment-considerations/26502/ Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are o…
  continue reading
 
CME credits: 1.25 Valid until: 16-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/fixed-duration-vs-continuous-dosing-approaches-in-cll-impact-on-qol-and-toxicity-risk/26500/ Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients …
  continue reading
 
CME credits: 1.25 Valid until: 16-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/risk-stratification-in-newly-diagnosed-cll/26494/ Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with signi…
  continue reading
 
Loading …

คู่มืออ้างอิงด่วน